Is IntelyCare profitable in 2026?

No public profitability data is available for IntelyCare. Revenue estimates conflict wildly, from $38M (2024, RocketReach) to $77.7M (ZoomInfo, July 2026), and the company has cut headcount 33.2% since 2023, suggesting cost pressure rather than confirmed profitability.

Is IntelyCare laying off employees?

Yes. IntelyCare underwent three layoff rounds in 13 months (December 2022, June 2023, January 2024), with one round cited as a ~40% corporate headcount cut. Total headcount fell 33.2% from 3,047 in 2023 to 2,036 by Q4 2025.

What is IntelyCare's current valuation?

Unclear and contested. Its last priced round was $1.1B in April 2022 (Series C). Secondary-market trackers disagree sharply: Forge Global implies $3.21B as of December 2025, while TrueUp estimates roughly $0.3B as of mid-2026, a 73% markdown.

Who is IntelyCare's biggest competitor?

The most structurally dangerous rival is AMN Healthcare, a ~$3B revenue traditional staffing incumbent with existing W-2 infrastructure and facility relationships that is not blocked by IntelyCare's regulatory moat. Direct app-based rivals include Clipboard Health, ShiftKey, ShiftMed, and connectRN.

Could AI replace IntelyCare?

Not directly. AI-driven shift-matching is now commodity across the sector, but IntelyCare's actual moat is its 50,000+ credentialed W-2 nurse network, facility contracts, and state registrations like New York's Article 29-K, none of which AI can shortcut.

IntelyCare is privately venture-backed, last priced at $1.1B in an April 2022 Series C led by Janus Henderson Investors with Longitude Capital, Leeds Illuminate, Endeavour Vision, Revelation Partners, and Kaiser Permanente Ventures. No IPO has been filed as of 2026.

Job boards and HR platforms · United States

IntelyCare

intelycare.com ↗

App-based marketplace matching W-2 nurses to hospitals and nursing homes.

Losing its protection

Assessed 22 July 2026 · Evidence as of 22 July 2026

The structural protection is eroding.

On the recordSince 22 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: Next priced funding round to resolve $3.21B vs $0.3B valuation gap

The call

IntelyCare's licensing and network edge blocks gig-app clones, but shrinking headcount and a possible 73% valuation cut show the business itself is under pressure.

IntelyCare runs a marketplace that matches nurses (mostly full-time employees on its payroll) with short-term jobs at hospitals and care facilities. It is hard to copy because IntelyCare has tens of thousands of credentialed nurses already signed up, contracts locked in with hospitals, and special state licenses (particularly in New York) that keep cheaper competitor apps from operating legally. However, IntelyCare has fired one third of its staff in two years and is worth a fraction of what it was in 2022; bigger rivals like AMN Healthcare and Clipboard Health already have the same nurse networks and can build app-like matching tools. The one thing that could change the picture is whether the company's recent purchase of CareRev keeps growing fast enough to prove the marketplace still works, or whether it drains cash and scares nurses and hospitals away instead.

Why

AI pressure: None apparent. Shift-matching algorithms are now commodity tech; AI can't shortcut the W-2 licensing and network liquidity IntelyCare already built. Could AI do the core job? Only partly.

Bigger players: AMN Healthcare. AMN has the W-2 infrastructure, facility relationships, and compliance history to bolt an app-native model onto its existing $3B staffing business. Could a giant copy it? Probably.

What protects it. Credentialed W-2 nurse network, facility contracts, and state licensing like New York's Article 29-K that 1099 rivals can't legally match.

What would change this call

IntelyCare announces a new priced funding round within 12 months. Would clarify whether valuation is near $1.1B or has fallen toward $0.3B.
Reported outcome of misclassification litigation tied to CareRev or IntelyCare. Would show whether W-2 model faces new legal cost pressure.
IntelyCare job postings or headcount stabilize or continue declining in 2026 filings. Would indicate whether contraction has bottomed or is deepening.

Key numbers

$1.1B last priced valuation (2022-04-06)
33% headcount drop, 2023 to 2025 (2025-12-31)
Secondary est. implies $0.3B, 73% markdown (2026-06-30)

Named risks

73% secondary-market valuation markdown to ~$0.3B implies underwater equity for employees and investors. Severity: high
Three layoff rounds in 13 months and 96% job-posting collapse signal ongoing contraction. Severity: high
Multi-state contractor misclassification litigation risk, amplified by CareRev acquisition exposure. Severity: high
Fragmented, unresolved state-by-state gig-staffing regulation could cut either way on compliance costs. Severity: medium
Conflicting, unverifiable revenue and headcount figures across data sources undermine investor confidence. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
AMN Healthcare	gaining on	~$3B revenue W-2 incumbent not blocked by IntelyCare's regulatory moat, as of 2023
Clipboard Health	losing to	Forced to exit New York in 2025 after state reclassified gig-nursing apps as staffing agencies
Cross Country Healthcare	gaining on	Traditional W-2 staffing incumbent capable of building app-native model without regulatory barrier
ShiftKey	contesting	Present in 40+ states, competing directly for same per-diem shifts (vendor-claimed, 2026-03-17)
ShiftMed	contesting	Direct app-based per-diem nurse staffing competitor in same category as of 2026
Nomad Health	contesting	Raised $105M in June 2022, competing in travel-nurse and allied-health staffing

Questions people ask

Is IntelyCare profitable in 2026?: No public profitability data is available for IntelyCare. Revenue estimates conflict wildly, from $38M (2024, RocketReach) to $77.7M (ZoomInfo, July 2026), and the company has cut headcount 33.2% since 2023, suggesting cost pressure rather than confirmed profitability.
Is IntelyCare laying off employees?: Yes. IntelyCare underwent three layoff rounds in 13 months (December 2022, June 2023, January 2024), with one round cited as a ~40% corporate headcount cut. Total headcount fell 33.2% from 3,047 in 2023 to 2,036 by Q4 2025.
What is IntelyCare's current valuation?: Unclear and contested. Its last priced round was $1.1B in April 2022 (Series C). Secondary-market trackers disagree sharply: Forge Global implies $3.21B as of December 2025, while TrueUp estimates roughly $0.3B as of mid-2026, a 73% markdown.
Who is IntelyCare's biggest competitor?: The most structurally dangerous rival is AMN Healthcare, a ~$3B revenue traditional staffing incumbent with existing W-2 infrastructure and facility relationships that is not blocked by IntelyCare's regulatory moat. Direct app-based rivals include Clipboard Health, ShiftKey, ShiftMed, and connectRN.
Could AI replace IntelyCare?: Not directly. AI-driven shift-matching is now commodity across the sector, but IntelyCare's actual moat is its 50,000+ credentialed W-2 nurse network, facility contracts, and state registrations like New York's Article 29-K, none of which AI can shortcut.
Who owns IntelyCare?: IntelyCare is privately venture-backed, last priced at $1.1B in an April 2022 Series C led by Janus Henderson Investors with Longitude Capital, Leeds Illuminate, Endeavour Vision, Revelation Partners, and Kaiser Permanente Ventures. No IPO has been filed as of 2026.

Timeline

2026-06-22CareRev signs new Dallas hospital deal under its own brand post-acquisition
2026-01-08IntelyCare acquires CareRev to extend into acute/hospital staffing
2025-12-31Headcount down 33.2% since 2023 to 2,036; job postings fall to 8 for the year
2025-08-24Fourth Circuit affirms $9.3M FLSA misclassification judgment vs a peer staffing agency
2025-01-01New York reclassification forces Clipboard Health, Nursa, KARE to exit state (2025)
2024-07-31Matthew Levesque appointed CEO of IntelyCare
2024-01-31Third layoff round within 13 months
2023-08-01David Coppins steps down as CEO to Executive Chairman
2023-06-30Second layoff round, cited as ~40% corporate workforce reduction
2022-04-06IntelyCare closes $115M Series C at $1.1B valuation

Revision history

22 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Deel Beisen Holdings Saramin HR